Sydney, Australia 6 June 2018 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce the appointment of Michelle Parker as Head of Clinical Operations at Clarity.
Michelle has enjoyed a diverse career spanning across Nuclear Medicine/PET and pharmaceutical industries, both locally and abroad over the last 20 years. Michelle joins Clarity from Novartis, a leading global pharmaceutical company, where she worked for 10 years and most recently held the position of Head of International Clinical Research Operations, leading a multi-disciplinary, high performing team of over 35 associates responsible for end-to-end clinical trial programming. In this role, she delivered beyond expectations in the establishment of the local clinical studies initiative, a first for the Asia-Pacific region.
Prior to working in the pharmaceuticals industry, Michelle held the role of Deputy Chief Technologist at Royal Marsden Hospital, London, UK, where she played an integral role in the development and set up of PET/CT imaging within the Nuclear Medicine Department. She also has worked in a number of hospitals as a Nuclear Medicine Technologist and has acquired strong operational knowledge and leadership experience in the nuclear medicine and clinical development fields throughout her career.
With her nuclear medicine expertise, and her drive for building progressive and successful teams, Michelle commented on her appointment “I am delighted to be joining Clarity and to capture the opportunity to merge my two passions, nuclear medicine and clinical trials. It is an exciting time for Clarity and I am looking forward to helping shape the agenda for the clinical trial strategy and to being part of a highly engaged, enthusiastic and innovative team.”
Clarity’s Executive Chairman Dr Alan Taylor said: “We are excited to welcome Michelle to our team and are looking forward to working together on progressing Clarity’s clinical trials. Michelle’s in-depth experience of clinical research operations will be invaluable for Clarity as we actively progress our products through clinical trials and develop new pipeline products to provide better diagnostic and therapeutic treatments for adults and children with cancer.”
Michelle holds a B.Sc of Applied Science in Medical Radiation Technology (Nuclear Medicine) from the University of Sydney.
About Clarity
Clarity is a personalised medicine company focused on the treatment of serious diseases. The Company is a leader in innovative radiopharmaceuticals, developing targeted therapies for the treatment of cancer and other serious diseases in adults and children.
www.claritypharmaceuticals.com
Media Contact
Dr Alan Taylor
Executive Chairman
Ph: +61 (0)413 871 165
E: ataylor@claritypharm.com
